BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Dec 20, 2012
 |  BC Innovations  |  Strategy

MRC Technology extends reach

After six years of focusing on developing small molecule drug candidates and humanizing therapeutic mAbs, both mostly from U.K. source, MRC Technology, the commercialization arm of the country's Medical Research Council, is taking its search for new assets to Asia. MRC Technology has taken its first steps on that front through a deal with the Shanghai Institute of Biochemistry and Cell Biology, part of the Chinese Academy of Sciences.

The MRC is the U.K.'s largest publicly funded biomedical research organization. MRC Technology initially provided technology transfer services exclusively to MRC but now works with multiple charitable and academic organizations.

MRC Technology is a not-for-profit technology transfer company that offers IP management and commercial development of healthcare-related science to scientific organizations. The income generated helps fund further research in the originating scientific organizations.

The company has an in-house screening facility, chemical libraries of about 120,000 compounds and the medicinal chemistry expertise of researchers at MRC Technology's Centre for Therapeutics Discovery. In addition, MRC Technology has access to about 100,000 proprietary compounds that are target-based and 22 shelved compounds through a deal with AstraZeneca plc.

Under MRC Technology's deal with the Shanghai Institute of Biochemistry and Cell Biology (SIBCB) to identify new targets for drug development, the institute will share access to potential new targets, which can be further developed at the Centre for Therapeutics Discovery.

"We are always looking for innovative science that might be attractive to pharmaceutical companies further down the drug discovery pipeline," said Michael Dalrymple, director of business development at MRC Technology.

According to Zi Zhang, MRC Technology's business development manager in charge of the partnership, "We chose SIBCB because of its long history and past achievements and because of it being recognized as a flagship institute by the...

Read the full 1459 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$100 USD
More Info >